Provectus Pharmaceuticals Inc. Announces Preliminary Phase 2 Data For PH-10 in its Psoriasis and Atopic Dermatitis Trials

Bookmark and Share

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.
MORE ON THIS TOPIC